GI
CNTA

GAMMA Investing’s Centessa Pharmaceuticals CNTA Stock Holding History

GAMMA Investing’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,980
Closed -$158K – 4157
2026
Q1 		$158K Buy
3,980
+365
+10% +$9.34K 0.01% 1286
2025
Q4 		$90.4K Buy
3,615
+3
+0.1% +$76 ﹤0.01% 1654
2025
Q3 		$87.6K Buy
3,612
+421
+13% +$7.48K ﹤0.01% 1597
2025
Q2 		$41.9K Sell
3,191
-1,104
-26% -$14K ﹤0.01% 2036
2025
Q1 		$61.8K Buy
4,295
+458
+12% +$7.49K ﹤0.01% 1641
2024
Q4 		$64.3K Buy
3,837
+865
+29% +$14.3K 0.01% 1452
2024
Q3 		$47.5K Buy
2,972
+1,509
+103% +$18.5K ﹤0.01% 1532
2024
Q2 		$13.2K Sell
1,463
-35
-2% -$332 ﹤0.01% 2090
2024
Q1 		$16.9K Buy
1,498
+931
+164% +$8.82K ﹤0.01% 1759
2023
Q4 		$4.64K Buy
+567
New +$3.8K ﹤0.01% 2271

GAMMA Investing's CNTA Position: Q2 2026 in Review

GAMMA Investing sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 3,980 shares — an estimated $158K sold.

GAMMA Investing first reported a position in CNTA in Q4 2023 and held it in 10 quarters. The position peaked at $158K in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

  • GAMMA Investing reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • GAMMA Investing sold 3,980 Centessa Pharmaceuticals shares in Q2 2026, an estimated $158K.
  • GAMMA Investing first reported a position in Centessa Pharmaceuticals in Q4 2023 and held it in 10 quarters.
  • GAMMA Investing's Centessa Pharmaceuticals position peaked at $158K in Q1 2026.
  • 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.